Recent Updates
Recently added Catalysts

Pasithea Therapeutics Corp.

KTTAFDA catalysts, PDUFA dates & pipeline intelligence
$0.58
▲ +0.06 · +11.31%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full KTTA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.2852W HIGH $2.06
Volume
436.91 K
Value Traded
239.21 K
Short % Float
0.54%
Days to Cover
1.6
+57.28%Week
+23.81%1 Month
+22.11%3 Month
-26.85%6 Month
-99.13%5 Year
-99.13%All Time

Cash Data

Unlock KTTA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
19.34 M
EPS (TTM)
-0.64
P/E Ratio
-
Ent. Value
-26.32 M
Total Shares
33.40 M
Float Shares
32.21 M
Insiders
3.59%
Institutions
60.32%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1/1b data presentation
PAS-004
Plexiform neurofibromas (NF1)
Phase 1/1bSmall MoleculesNervous System
Unlock every KTTA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

KTTA Catalyst Timeline

Dated clinical, regulatory and corporate events for Pasithea Therapeutics Corp.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Pasithea Therapeutics Corp.

179Total events
7Upcoming
24Tier-1 (high impact)
2020 to 2026Coverage

Upcoming catalysts 2

T1Interim Analysis
Subscribe to view catalyst details
PAS-004
T1Topline Readout
Subscribe to view catalyst details
PAS-004

Event history 50

▲IND ClearancePAS-004IND
FDA cleared IND for PAS-004 in NF1-associated cNF
NF1-associated cutaneous neurofibromas (cNF)source ↗
▲Trial InitiationPAS-004Trial
Phase 2 trial of PAS-004 in cNF may proceed following IND clearance
NF1-associated cutaneous neurofibromas (cNF)source ↗
●Poster PresentationPAS-004Presentation
Poster 1050P of Phase 1 PAS-004 safety/PK data presented at ESMO Congress 2026
MAPK pathway-driven advanced solid tumorssource ↗
▲Safety Data UpdatePAS-004Clinical Data
Updated safety/tolerability data: no DLTs, no Grade ≥3 TRAEs, MTD not reached
MAPK pathway-driven advanced solid tumorssource ↗
●Enrollment UpdatePAS-004Trial
37 patients enrolled across 10 dose cohorts in Phase 1 dose escalation
MAPK pathway-driven advanced solid tumorssource ↗
▲Additional DataPAS-004Clinical Data
Prolonged stable disease in four patients >300 days, two >500 days
MAPK pathway-driven advanced solid tumorssource ↗
▲PK PD DataPAS-004Clinical Data
PK data: ~58-hour half-life, Cmax/Cmin <1.5, linear PK
MAPK pathway-driven advanced solid tumorssource ↗
◆Quarterly UpdateCorporate
One-on-one investor meetings at Cantor Global Healthcare Conference
▲Interim AnalysisPAS-004Trial
Interim Phase 1 safety and clinical activity data for PAS-004
MAPK pathway-driven advanced solid tumors with RAS, NF1 or RAF mutationsource ↗
●Protocol AmendmentPAS-004Trial
Protocol amendment to extend dose escalation to higher levels (18mg-52mg) and initiate pilot food effect assessment
MAPK pathway-driven advanced solid tumors with RAS, NF1 or RAF mutationsource ↗
Unlock the full KTTA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How KTTA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-04PAS-004 Phase 1 data presentation Phase 1
Unlock 1 more KTTA historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 56%
Micro Cap
(rank 375 of 668)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
PAS-004 Small MoleculesNCT06961565NF1 MutationPhase 1 RECRUITING 56Feb 1, 2028
PAS-004 Small MoleculesNCT06299839RAS MutationPhase 1 RECRUITING 83Sep 1, 2027
Unlock the KTTA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every KTTA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
PAS-004
Fast TrackOrphanRare Pediatric
advanced solid tumorsPhase 12026-10-23prolonged stable disease: four patients; duration on drug: more than 300 days; longest duration: over 500 days; half life: approximately 58 hours; grade 3 adverse events: none; treatment related AEs: low-grade and manageable; patients on study: four patientsRead MorePasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026Read More
Scroll for more · summaries link to the source press release
Unlock every KTTA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock KTTA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Coastlands Capital LP10% OwnerBuy 100,000 3,835,035 held$0.53 06/17/2026
Unlock the full KTTA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Opaleye Management Inc. 0.1 % 1.06 M 2.05 M
Unlock every fund holding KTTA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in KTTA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see KTTA ownership
Insider and institutional ownership, quarter by quarter.

KTTA Short Interest

Shares sold short, counted twice a month.

0.54%
Short % of Float
of tradable shares sold short
174.6K
Shares Sold Short
+9.2% vs prior count
1.6 Low
Days to Cover
trading days of normal volume to buy every short share back
111.9K
Avg Daily Volume
the average used for days to cover
Unlock KTTA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock KTTA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live KTTA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock KTTA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How KTTA ranks across every disease it competes in

Competitive Position is a premium feature
See how KTTA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

KTTA News

KTTA
Nov 3, 2026
KTTAFDA Updates
▲ +44%on this news· ran to +57% by day 3

Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)

Pasithea Therapeutics announced FDA clearance for its IND application for PAS-004, targeting NF1-associated cutaneous neurofibromas (cNF). This Phase 2 trial aims to evaluate PAS-004, a novel oral MEK inhibitor, in patients suffering from this condition, which affects over 95% of NF1 patients. Currently, there are no FDA-approved systemic therapies for cNF.

Read more →
KTTA
Oct 28, 2026
KTTAConferences/Events
▼ -6%on this news· ran to +35% by day 3shared move

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

Pasithea Therapeutics announced a virtual KOL event on November 4, 2026, focusing on NF1 treatment. Key opinion leaders will discuss current challenges and the potential of PAS-004, a macrocyclic MEK inhibitor. The event aims to address unmet medical needs in treating neurofibromas associated with neurofibromatosis type 1.

Read more →
KTTA
Oct 23, 2026
KTTAPhases
▼ -9.1%on this newsshared move

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

Pasithea Therapeutics announced positive results from its Phase 1 study of PAS-004, showing prolonged stable disease in four heavily pre-treated cancer patients. The drug demonstrated a favorable safety profile with no Grade 3 adverse events and a long half-life of approximately 58 hours. These results were presented at the ESMO Congress 2026.

Read more →
KTTA
Sep 14, 2026
KTTAPhases

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics announced it will present initial clinical data from its Phase 1/1b trial of PAS-004 at the 2026 European Neurofibromatosis Conference. The presentations include an oral presentation on cutaneous neurofibromas and a poster on plexiform neurofibromas. This marks the company's first public disclosure of clinical data from the trial.

Read more →
KTTA
Sep 3, 2026
KTTAConferences/Events

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

Pasithea Therapeutics Corp. announced its participation in two investor conferences in September 2026. The company will hold one-on-one meetings at the Cantor Global Healthcare Conference and present at the H.C. Wainwright Global Investment Conference. This engagement highlights Pasithea's ongoing development of PAS-004, a macrocyclic MEK inhibitor for chronic diseases.

Read more →
KTTA
Jul 21, 2026
KTTAConferences/Events

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

Pasithea Therapeutics has announced that its Phase 1 dose-escalation study of PAS-004 will be presented at the ESMO Congress 2026. The study focuses on the safety and pharmacokinetics of PAS-004 for patients with MAPK pathway-driven advanced solid tumors. The presentation is scheduled for October 23, 2026, in Madrid, Spain, with further details to be released at that time.

Read more →
KTTA
Jul 8, 2026
KTTAConferences/Events

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

Pasithea Therapeutics Corp. announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit on July 16, 2026. The summit will focus on various neurological and psychiatric disorders, featuring investor meetings and discussions. Pasithea's management will be available for one-on-one meetings, highlighting their ongoing clinical trials for PAS-004, a macrocyclic MEK inhibitor.

Read more →
KTTA
Jun 30, 2026
KTTAPhases

Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Pasithea Therapeutics has reported positive interim data from its Phase 1 trial of PAS-004, a MEK inhibitor for advanced cancer patients. The drug demonstrated a favorable safety profile, with all treatment-related adverse events classified as Grade 1 or 2. Notably, some patients exhibited stable disease for over six months, surpassing typical progression-free survival rates for similar treatments. The company plans to expand dose escalation and assess food effects on drug pharmacokinetics.

Read more →
KTTA
Jun 16, 2026
KTTAPhases
▼ -8.9%on this news

Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial

Pasithea Therapeutics has amended its Phase 1/1b clinical trial protocol for PAS-004 in NF1 patients. The updates include additional dose levels and an extended treatment period, allowing for more comprehensive data collection. The company has successfully enrolled additional patients and aims to provide interim data in Q4 2026.

Read more →
KTTA
Jun 15, 2026
KTTAConferences/Events
▼ -5.3%on this news· ran to -15% by day 3shared move

Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference

Pasithea Therapeutics will exhibit at the Children's Tumor Foundation 2026 NF Conference in Denver, Colorado, from June 26-30, 2026. The company aims to engage with the NF1 community following recent FDA designations for its lead treatment candidate, PAS-004. CEO Dr. Tiago Reis Marques emphasized the importance of collaboration to enhance outcomes for NF1 patients.

Read more →
KTTA
Jun 2, 2026
KTTAFDA Updates
▼ -9.8%on this news

Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Pasithea Therapeutics announced that the FDA has granted Orphan Drug Designation to its drug PAS-004 for treating Amyotrophic Lateral Sclerosis (ALS). This designation is significant due to the limited treatment options available for ALS, a disease with a high unmet medical need. The company is also conducting clinical trials to explore PAS-004's efficacy and safety.

Read more →
KTTA
May 4, 2026
KTTAGeneral

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Pasithea Therapeutics has appointed Dr. Kartik Krishnan as Chief Medical Officer, effective May 1, 2026. Dr. Krishnan will lead clinical development for PAS-004, a MEK inhibitor targeting neurofibromatosis type 1. His extensive experience in advancing therapies is expected to enhance the company's efforts in this area.

Read more →
KTTA
Apr 20, 2026
KTTAFDA Updates

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics has received Rare Pediatric Disease Designation from the FDA for PAS-004, a treatment for Neurofibromatosis type 1 (NF1). This designation is significant as NF1 affects approximately 115,000 individuals in the U.S. The company is also conducting Phase 1/1b trials for PAS-004 in patients with NF1-associated plexiform neurofibromas.

Read more →
KTTA
Apr 1, 2026
KTTAFDA Updates

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics Corp. has received Fast Track designation from the FDA for its drug PAS-004, aimed at treating neurofibromatosis type 1 (NF1) associated plexiform neurofibromas. This designation allows for early and frequent communications with the FDA, facilitating product development. The company is currently engaged in Phase 1/1b clinical trials for this treatment, which addresses the serious health risks posed by plexiform neurofibromas in NF1 patients. The Fast Track status may allow for quicker regulatory approval processes if relevant criteria are met.

Read more →
KTTA
Feb 17, 2026
KTTAConferences/Events

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics Corp. will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. CEO Tiago Reis Marques will discuss the company's lead drug candidate, PAS-004, which is currently in clinical trials for treating NF1-associated plexiform neurofibromas. The presentation will be available via webcast, and management will hold one-on-one meetings with investors.

Read more →
KTTA
Jan 13, 2026
KTTAPhases

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics has provided an update on its PAS-004 clinical programs, highlighting positive early results from its Phase 1 trial in advanced cancer patients and ongoing trials for neurofibromatosis type 1. The company raised $60 million to support these initiatives, aiming to address significant unmet medical needs. However, they acknowledge the inherent risks in clinical trial outcomes and regulatory approvals.

Read more →
KTTA
Dec 2, 2025
KTTAGeneral

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics has successfully closed a public offering of 80 million shares, raising approximately $60 million. The offering was led by notable healthcare investors and aims to support the company's ongoing clinical trials and research initiatives. The funds will enhance the company's cash runway, expected to last until at least mid-2028.

Read more →
KTTA
Nov 28, 2025
KTTAGeneral
▲ +38.7%on this newsshared move

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Corp. has announced the pricing of a public offering of 80 million shares at $0.75 each, aiming to raise approximately $60 million. The offering is set to close around December 1, 2025, and will support the company's ongoing research and development efforts, particularly for its lead drug candidate, PAS-004. The offering is facilitated by H.C. Wainwright & Co. and is backed by several healthcare-focused investors.

Read more →
KTTA
Nov 25, 2025
KTTAPhases
▲ +14.8%on this news· ran to +173% by day 3shared move

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

Pasithea Therapeutics Corp. has announced that it has been awarded a $1 million grant from the ALS Association to conduct a clinical trial for its drug PAS-004 in amyotrophic lateral sclerosis (ALS) patients. The trial will assess the safety, tolerability, and efficacy of PAS-004, a next-generation macrocyclic MEK inhibitor, which has previously shown promising results in animal models. This funding will facilitate the initiation of the first human clinical trial for PAS-004 aimed specifically at ALS, marking a significant milestone for the company.

Read more →
KTTA
Nov 24, 2025
KTTAPhases
▲ +45.3%on this news· ran to +403% by day 3shared move

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

Pasithea Therapeutics has completed Cohort 7 of its Phase 1 trial for PAS-004, a MEK inhibitor for advanced cancer patients. The trial reported no treatment-related adverse events and demonstrated a favorable pharmacokinetic profile. The safety review committee has recommended escalating to Cohort 8, indicating positive momentum for the drug's development.

Read more →

About Pasithea Therapeutics Corp.

Miami Beach, FL 5 employees pasithea.com
Headquarters1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH, FL, 33139
BIOPHARMAWATCH ELITE PLUS
Trade the next KTTA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime